“SkinBioTherapeutics plc significant progress in the past six months” Dr. Cath O’Neill, CEO

SkinBioTherapeutics plc (LON:SBTX) a life sciences company focused on skin health, has announced its half year results for the six months to 31 December 2017.

 

— Significant progress in developing the SkinBiotix(R) technology; successful initial lysate manufacture scale-up

— Three different formulation options for the cosmetic application are being assessed ahead of the human study scheduled in Q3 2018

— Anti-infection and eczema programmes progressing – application frequency and safe dosing levels determined

— Early stage commercial discussions with significant industry players continuing with respect to the cosmetic application

   --     Cash as at period end at GBP3.6m (2016: GBP0.4m)

Dr. Cath O’Neill, CEO of SkinBioTherapeutics, said: “We have made significant progress in the past six months around our SkinBiotix(R) technology and we are on track with the advancement of all three indications in cosmetics, anti-infection and eczema.

Our primary focus has been on developing the cosmetic application. Manufacturing scale-up and formulation is progressing to plan. As laid out at IPO, we intend to carry out the human safety study later this year.

There is a growing awareness of our SkinBiotix(R) platform technology from the skin healthcare industry, based on the reputation of our team and our ‘science-led’ business approach. With continued work on our technology and the start of human studies in Q3, we are building further value for shareholders and a strong position from which to hold potential commercial discussions.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    SkinBiotherapeutics Plc

    More articles like this

    SkinBiotherapeutics Plc

    Why we should all be eating a microbiome diet

    First, let’s briefly talk about the microbiome. The gut microbiome refers to the trillions of bacteria that live within our gastrointestinal tracts. If you were to collectively bunch them all up into a ball, it would

    SkinBiotherapeutics Plc

    Microbiome-based therapy for eczema: On the horizon?

    Results of pre-clinical and early clinical trials conducted by investigators at the National Institutes of Health showing the effectiveness of using bacteria to treat eczema are paving the way for further study into the potential for

    SkinBiotherapeutics Plc

    SkinBioTherapeutics plc achieved significant manufacturing scale up

    Dr Cath O’Neill, CEO of SkinBioTherapeutics, commented: “The progress we’ve made so far in manufacturing and freeze-drying the lysate is very encouraging. The current formulation is undergoing extended stability studies in preparation for the human study.”

    SkinBiotherapeutics Plc

    Protect your skin microbiome

    Like your gut, your skin also has a complex system of bacteria and fungi living on its surface. “It sounds weird and scary, but it’s actually good for you,” says Sarvenaz Zand, M.D., a dermatologist based

    SkinBiotherapeutics Plc

    What Is Dyshidrotic Eczema, Exactly?

    If you have found your way to this story, then there is a good chance you’re feeling the itch. Dyshidrotic Eczema is a common form of eczema that can crop up as crazy itchy blisters on

    SkinBiotherapeutics Plc

    Bacteria on your skin could speed healing

    Microbes on the surface of the skin help the immune system to respond to injury and heal wounds. Immunity research have historically focused on the response to pathogens and inflammation, and so relatively little is known

    SkinBiotherapeutics Plc

    Can you really use probiotics to fight acne?

    If you’ve ever had a breakout, you’ve likely tried to dry those suckers up with bacteria-killing washes and spot treatments. You know, because conventional wisdom (and lots of research) has shown that zits, particularly the big painful

    SkinBiotherapeutics Plc

    SkinBiotherapeutics is harnessing the power of Microbiome

    SkinBioTherapeutics (LON:SBTX) CEO Dr Cath O’Neill worked in the field of gastroenterology, investigating the effect of probiotics on the intestinal barrier function, an area which had already seen significant commercial success through health foods and yoghurt

    SkinBiotherapeutics Plc

    Skin Microbiome: Why You want Bacteria On Your Skin

    The gut gets the majority of the attention when we talk about the microbiome (even though your mouth has a vast microbiome as well!). The digestive system is home to trillions of organisms that can affect the body,